Toronto, Ontario--(Newsfile Corp. - November 3, 2016) - THE JENEX CORPORATION (TSXV: JEN.H) ("Jenex" or the "Corporation"), Rob
Fia, CEO and Chairman of Jenex, reports the Corporation has entered into an exclusive license agreement (the "License") with
Luminar Media Group Inc. of Aventura, Florida to market Jenex's next generation thermal therapy insect device (the "Device").
Luminar has an extensive contact base with Over the Counter ("OTC") retail distribution channels in the US. Europe and Asia. The
License is subject to TSX Venture Exchange approval.
The License allows Luminar the exclusive right to market the Device in all markets outside of Canada including the United
States, Europe and Asia. Jenex maintains the marketing rights for the Canadian market and will own all intellectual property
related to the Device. Jenex is investigating various names to identify the Device and a trademark. The Device will incorporate a
proprietary silver anti-microbial coating along with other new features. As previously announced, Jenex is working with Microbonds
Inc., an advanced coatings and electrical design company, to complete the design of the Device. Jenex expects to have a working
Device prototype in the next 30-45 days.
Jenex is pleased to announce it has received an initial USD $25,000 as outlined in the License, which includes the following
additional milestone payments:
-
USD $25,000 by November 15th, 2016
-
USD $75,000 by December 15th, 2016
-
USD $125,000 by February 28th, 2017
Jenex will receive a royalty payment equal to 10% of gross sales of the Device up to the first 100,000 units sold and 5% of
gross sales of the Device thereafter. The royalty is payable quarterly. Luminar must meet minimum sales targets of 10,000 units
sold in the first 12 months from signing the License, 50,000 units sold by 24 months following the signing of the License and
100,000 units sold by 36 months from signing of the License. Luminar must continue to sell a minimum of 100,000 units per year
beyond 36 months from signing of the License.
In exchange for the above milestone and royalty payments Jenex will commit to obtaining all regulatory approvals with the FDA
and other regulatory requirements in jurisdictions outside of the U.S. deemed necessary to market the product. Jenex will use its
current FDA license for its former thermal therapy insect device and intends to apply for a Class II medical device that is
indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites including bees,
wasps, hornets, mosquitoes, black flies, and jelly fish. Jenex received approval for the above claims from the FDA (United States)
in 1997. Jenex will utilize its ISO 13485 Quality Management System in any market that Luminar intends to market.
Rob Fia, CEO & Chairman of The Jenex Corporation comments:
"We are pleased to be partnering with Luminar to market our new Device. We believe our next generation product will be
revolutionary and rewarding for both companies. This License is an exciting development for our Company and shareholders and is due
to 'Outside the Box' thinking at Luminar and all the hard work of our staff and valuable partners that have contributed to date. We
will have more to report as we work towards finalizing a working prototype of the Device."
Chris Cook, Chairman of Luminar comments:
"We are very excited about our new partnership with The Jenex Corporation. The license agreement is an excellent
opportunity for Luminar to increase shareholder value by leveraging Jenex's unique thermal therapy device. Luminar will bring
specialized expertise in marketing and digital media capabilities to the partnership with Jenex as we expand globally with this
important new treatment device."
About Jenex:
Jenex is a progressive medical device technology company focused on providing consumers with quality medical devices that
address their dermatological needs. Clear and healthy skin for all is at the core of Jenex's philosophy as is the belief that
such outcomes should not be a privilege for only those who can afford costly procedures and treatments. The Company's
breakthrough proprietary thermal therapy technology uses heat and light energy to deliver effective, non-invasive and pain free
skin care. The Jenex Corporation trades on the NEX (TSXV: JEN.H). For more information visit: www.thejenexcorporation.com or www.interceptcs.com
About Luminar:
The Luminar Media Group has extensive knowledge and experience in the media, marketing and entertainment industries. Our
company was started by entrepreneurs that have a vision to identify new tools to communicate with the audience. Our presence
is a natural response to a new way of working in a changing landscape. At Luminar, we embrace the challenge of the constantly
evolving business landscape and our determined culture will develop solutions that evolve with the changing business paradigm. For
more information contact us at Luminar Media Group Investor Relations, ir@gdee.rocks or
visit us at www.gdee.rocks
Forward Looking Statements
This press release contains forward-looking statements. More particularly, this press release contains statements which include
the timing of the proposed Device prototype and the commitment of Jenex to obtain all regulatory approvals with the FDA and other
regulatory requirements in jurisdictions outside the US. The forward-looking statements are based on certain expectations and
assumptions made by Jenex. Although Jenex believes that those expectations and assumptions are reasonable, undue reliance should
not be placed on the forward-looking statements because Jenex can give no assurance that they will prove to be correct. Since
forward-looking statements address future events and conditions, by their very nature they involve inherent risks and
uncertainties. Actual results could differ materially from those anticipated due to a number of factors and risks. In addition to
other risks, there is a risk that the development of the Device prototype and the obtaining of regulatory approvals with the FDA
and other regulatory requirements will be delayed. The forward-looking statements contained in this press release are made as of
the date hereof. Jenex disclaims any intention or obligation to update or revise any forward-looking statements whether as a result
of new information, future events or otherwise, except as required under applicable securities laws.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this release.
For Further information please contact:
The Jenex Corporation
Rob Fia
CEO & Chairman
Phone: (416) 722-4994
e-mail: rfia@thejenexcorporation.com
NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES
